Stock 5G3 TALKMED GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

TalkMed Group Limited

Equities

5G3

SG2G61000003

Healthcare Facilities & Services

Market Closed - Singapore S.E.
Other stock markets
 11:14:19 2024-04-18 pm EDT 		5-day change 1st Jan Change
0.41 SGD -2.38% Intraday chart for TalkMed Group Limited -3.53% +7.89%
Apr. 18 TalkMed Group Limited Approves Final One-Tier Tax-Exempt Dividend for the Financial Year Ended 31 December 2023 CI
Apr. 17 TalkMed Reaches Final Settlement in Mediation Related to Claims in Stem Med Stake Disposal MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about TalkMed Group Limited

TalkMed Group Limited Approves Final One-Tier Tax-Exempt Dividend for the Financial Year Ended 31 December 2023 CI
TalkMed Reaches Final Settlement in Mediation Related to Claims in Stem Med Stake Disposal MT
TalkMed Group Awards 1.1 Million New Shares MT
TalkMed's H2 Attributable Profit Falls on Wider Impairment Loss MT
Talkmed Group Limited Proposes Tax Exempt (One-Tier) Final Dividend for the Financial Year Ended 31 December 2023, Payable on 10 May 2024 CI
TalkMed Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
TalkMed Group Grants Nearly 8 Million Share Awards Under Performance Share Plan MT
TalkMed Group Limited Announces Management Changes CI
TalkMed Group Limited Announces Re-Designation of Leong Ching Ching from Non-Executive Director to Independent Non-Executive Director and Appoints as Chairman of the Remuneration Committee, Effective January 1, 2024 CI
TalkMed Group Limited Announces Re-Designation of S. Chandra Das from Independent Non-Executive Director to Non-Independent Non-Executive Director, Effective 1 January 2024 CI
TalkMed Group Limited Announces Re-Designation of Sitoh Yih Pin from Independent Non-Executive Director to Non-Independent Non-Executive Director, Effective 1 January 2024 CI
Talkmed Group Limited Appoints Khoo Kei Siong as Alternate Director to Ang Peng Tiam, Effective January 1, 2024 CI
TalkMed Group Limited Appoints Dr Tan Khai Tong as Independent Non-Executive Director, Member of the Remuneration Committee, Effective January 1, 2024 CI
TalkMed Group Limited Appoints Peter Sim Swee Yam as Independent Non-Executive Director, Chairman of the Nominating Committee, Member of the Audit and Risk Committee, Effective January 1, 2024 CI
TalkMed Group Limited Appoints Lam Kok Shang as Independent Non-Executive Director, Chairman of the Audit and Risk Committee, Member of the Nominating Committee, Effective January 1, 2024 CI
TalkMed Group Issues New Shares Upon Vesting of Share Awards MT
TalkMed Group Issues New Shares Upon Vesting of Share Awards MT
Singapore Stocks Track Global Gains to Close Higher; Delfi Shares Jump 3% on Higher H1 Profit, Revenue MT
TalkMed Group's Attributable Profit Zooms 18% in H1 MT
TalkMed Group Limited Declares Tax Exempt (One-Tier) Interim Dividend for the Financial Year Ending 31 December 2023, Payable on 22 August 2023 CI
TalkMed Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
TalkMed Group Establishes New Subsidiary for Cell, Gene Therapy MT
TalkMed Group Limited Approves the Final One-Tier Tax-Exempt Dividend in Respect of 2022 CI
TalkMed Group Limited Proposes to Declare Final One-Tier Tax-Exempt Dividend for the Financial Year Ended 31 December 2022 CI
TalkMed Group Issues Nearly 2 Million Shares Upon Vesting of Share Awards MT

Chart TalkMed Group Limited

Chart TalkMed Group Limited
More charts

Company Profile

TalkMed Group Limited is a Singapore-based investment holding company. The Company provides medical oncology and palliative care healthcare services in Singapore. Its oncology specialist specializes in providing medical oncology services targeting various cancers, such as breast cancer, colon cancer, lung cancer, liver, biliary and pancreatic cancers, gastro-intestinal cancers, head and neck cancers, leukemia, hematology malignancies and brain cancer. The Company, through the Parkway Cancer Centre (PCC)-vehicle, offers a support system to cater to the psychosocial needs of its patients and their families. The Company, through Singapore Cancer Centre (SCC) and the Parkway Cancer Centre (PCC) vehicle, provides CANSCREEN, a screening program that provides screening for individuals at a higher risk of getting cancer. The Company offers cellular and gene therapy related products and services. It also operates in Vietnam, Hong Kong and the People's Republic of China.
Sector
Healthcare Facilities & Services
Calendar
2024-07-29 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
TALKMED GROUP LIMITED Stock TalkMed Group Limited
+7.89% 409M
CVS HEALTH CORPORATION Stock CVS Health Corporation
-11.66% 87.46B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+12.72% 78.56B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+10.85% 29.37B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-11.36% 16.78B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-4.17% 16.01B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-6.85% 13.98B
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
+0.92% 12.31B
PURE HEALTH HOLDING Stock Pure Health Holding
-30.35% 12.07B
DAVITA INC. Stock DaVita Inc.
+22.01% 11.06B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. 5G3 Stock
  4. News TalkMed Group Limited
  5. TalkMed : Oncology Hospital JV in China Obtains Practice License